Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and ...

Full Year 2024 Results Key Financial Results Net loss: US$70.5m (loss widened ...

Thanks to an encounter with a real creature of the night, Batman has gone howling crazy and become a true-blue werewolf. Bruce Wayne may not believe in supernatural, but the supernatural has come ...

As of December 31, 2024, cash and cash equivalents were $111.0 million, compared to $134.3 million as of December 31, 2023. The Company also ...

Reports Q4 revenue $0 vs. $301,590. “Werewolf made considerable progress in 2024 with promising preliminary evidence of durable anti-tumor ...

“Werewolf made considerable progress in 2024 with promising preliminary evidence of durable anti-tumor activity and tolerability for cytokine therapeutics as we completed the dose-escalation ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half ...